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Abstract
To date, very large scale sequencing of many clinically important RNA viruses has been complicated by their high
population molecular variation, which creates challenges for polymerase chain reaction and sequencing primer design.
Many RNA viruses are also difficult or currently not possible to culture, severely limiting the amount and purity of available
starting material. Here, we describe a simple, novel, high-throughput approach to Norovirus and Hepatitis C virus whole
genome sequence determination based on RNA shotgun sequencing (also known as RNA-Seq). We demonstrate the
effectiveness of this method by sequencing three Norovirus samples from faeces and two Hepatitis C virus samples from
blood, on an Illumina MiSeq benchtop sequencer. More than 97% of reference genomes were recovered. Compared with
Sanger sequencing, our method had no nucleotide differences in 14,019 nucleotides (nt) for Noroviruses (from a total of 2
Norovirus genomes obtained with Sanger sequencing), and 8 variants in 9,542 nt for Hepatitis C virus (1 variant per
1,193 nt). The three Norovirus samples had 2, 3, and 2 distinct positions called as heterozygous, while the two Hepatitis C
virus samples had 117 and 131 positions called as heterozygous. To confirm that our sample and library preparation could
be scaled to true high-throughput, we prepared and sequenced an additional 77 Norovirus samples in a single batch on an
Illumina HiSeq 2000 sequencer, recovering .90% of the reference genome in all but one sample. No discrepancies were
observed across 118,757 nt compared between Sanger and our custom RNA-Seq method in 16 samples. By generating viral
genomic sequences that are not biased by primer-specific amplification or enrichment, this method offers the prospect of
large-scale, affordable studies of RNA viruses which could be adapted to routine diagnostic laboratory workflows in the near
future, with the potential to directly characterize within-host viral diversity.
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Introduction
Rapid, high-throughput and accurate whole genome sequenc-
ing of RNA viral pathogens such as Norovirus and Hepatitis C
virus (HCV) has enormous potential for the investigation of local
transmission and widespread dispersal [1]. Developing generic
methods that yield whole genomic sequence has been challenging
because the substantial genomic variation within circulating
populations of RNA viruses poses difficulties for primer design
[2]. Some RNA viruses are difficult or impossible to grow in tissue
culture precluding obtaining highly purified viral nucleic acid in
suitable concentrations for whole genome sequencing. The
challenges associated with non-culture-based approaches to
purifying viral RNA from samples such as faeces and blood that
are heavily contaminated by RNA from other sources has severely
limited the application of high-throughput sequencing [3]. Unlike
whole genome sequencing of bacteria, which is now well
developed [4][5][6][7][8], sequencing of viruses has therefore
not benefitted from dramatic advances in sequencing capacity.
Approaches for successfully sequencing RNA viruses have
previously been dependent, in some way, on target-specific
primer-based amplification of viral genomes [9]. These amplicons
can then be sequenced using Sanger sequencing or next-
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generation sequencing platforms such as Roche 454 and Illumina
[10]. Recent examples of this approach include studies of
Norovirus evolution [11] and HCV diversity [12]. Next-genera-
tion sequencing of amplicons and partial genome fragments from
RNA viruses have been used to investigate variants within
populations of Human Immunodeficiency Virus and HCV
infecting individual patients [13][14][15]. An enhancement on
this underlying amplification approach uses enrichment of target
viral sequences incorporating primers as ‘‘bait’’ to capture larger
genomic fragments [16][17]. All these approaches are expensive,
labour-intensive, slow and inflexible, and may require a priori
knowledge of partial or approximate virus sequence, utilising
different primers for different virus strain-groups. In turn,
assumptions about the sequences present can bias resulting data,
altering the representation of the viral genomic sequence at a
population level in a sample [18].
Here we adapt a strategy for high-throughput RNA sequencing
for use on RNA viruses present in blood and faeces using RNA
shotgun sequencing (RNA-Seq) [19][20]. We show that this
technology can not only generate near whole genome sequences,
but can also recover the sequence of multiple within-host variants
of highly diverse pathogens such as Norovirus and HCV. This
method may be deployed rapidly, and cheaply, using both
accessible bench-top and higher capacity platforms. The approach
can be used to successfully characterise un-culturable viral
genomes as an alternative to a PCR-amplicon based sequencing.
We anticipate that this efficient sequencing of variable RNA
viruses will bring a step change to both basic and translational
research.
Methods
Ethics Statement
This study was conducted in compliance with the Data
Protection Act (DPA number: Z5886415), and National Health
Service research governance. For Norovirus sampling, the
Modernising Medical Microbiology study protocol version 1.0
was approved by the Berkshire Research Ethics Committee on the
1st October 2010 (10/H0505/83) and the UK National Infor-
mation Governance Board (8-05(e)/2010). For HCV samples,
ethical approval was approved by the Oxfordshire Research Ethics
Committee A on the 15th April 2004, and patients gave written
informed consent for these samples to be used prior to sequencing
(04.OXA,010).
Sample Collection and Preparation
Faecal samples for Norovirus sequencing. Faecal samples
were collected during gastroenteritis outbreaks at the Oxford
University Hospitals NHS Trust Hospitals in 2010–2011, as part
of the infection service provision of the Trust. Reverse Transcrip-
tase Polymerase Chain Reaction (RT-PCR) [21] was used for
initial diagnostic confirmation of Norovirus in all faecal specimens.
Viral copy numbers were further determined by quantitative PCR
(qPCR) using genogroup specific Taqman probes and primers
[22].
Blood samples for HCV sequencing. Blood samples were
obtained from subtype-3a HCV infected, treatment naive patients
with chronic infection. Plasma was obtained by centrifugation and
stored within 5 hours of collection at 280uC. Patients were
recruited from the Oxford University Hospitals NHS Trust
Hospitals.
Total RNA Isolation
Faecal samples (Norovirus). Total RNA from faecal
samples was isolated using the Fujifilm Quickgene DNA tissue
kit SII under the manufacturer’s RNA extraction from stool
protocol for the Fujifilm Quickgene Mini-80 nucleic acid isolation
system (Fujifilm Corp., Tokyo, Japan). Three hundred microlitres
of supernatant from a 10% clarified emulsion of faeces was used to
prepare the lysate. Fifty microlitres of RNA was eluted from the
Mini-80 device. The resulting RNA samples were initially
quantified by Nanodrop spectrophotometer to estimate concen-
trations. Samples were stored in 280uC freezers between uses.
Plasma samples (HCV). Plasma was concentrated by high
speed centrifugation (23,6006 g for 1 h) at 4uC. In order to test
whether RNA samples available in archival sources are amenable
for high throughput sequencing using a simple workflow, we also
used RNA extraction methods currently implemented in many
clinical and research laboratories. For HCV, viral RNA was
extracted using a QIAmp viral RNA minikit (Qiagen, Hilden,
Germany) following the manufacturer’s protocol.
Library Preparation for Sequencing
Norovirus amplicon preparation for Sanger
sequencing. Reverse transcription and first strand cDNA
synthesis were performed using the Accuscript High Fidelity 1st
strand cDNA synthesis kit (Agilent, Santa Clara, California, USA)
following the manufacturer’s published protocol. PCR amplifica-
tion was then performed using specific in-house primers covering
the seven overlapping amplicons of the genome of Norovirus GII.4
(see Table S1), including internal primers to increase depth of
coverage using Sanger sequencing. PCR products were then
confirmed by agarose gel electrophoresis. The reaction products
were separated and detected with a Prism 3730 automated DNA
sequencer (Applied Biosystems, Foster City, CA, USA). Sequences
were assembled from the resultant chromatograms with the
STADEN suite of computer programs [23]. Primer sequences at
the 59 and 39 termini of the overlapping PCR amplicons were
excluded.
Hepatitis C Sanger sequencing. One-step reverse tran-
scription and first-round PCR in two reactions amplified a 4-kb
and a 7-kb product. Second-round nested PCR reactions used
.20 PCR primers in pairs generating 10 overlapping viral
genomic fragments each of approximately 1 kb, that were
sequenced and aligned manually to a reference sequence as
previously described [24].
Illumina RNA-Seq Library Preparation. Total RNA
quantity and integrity were assessed using Quant-IT RiboGreen
RNA Assay Kit (Invitrogen, Carlsbad, CA, USA) and Agilent
Tapestation 2200 R6K. Libraries for Illumina sequencing were
constructed from 100 ng of total RNA using the NEBNext mRNA
Sample Prep Kit 1 (New England Biolabs, Ipswich, MA, USA),
following the manufacturers’ guidelines with minor modifications:
end repair in 50 ml reaction volume (40 ml DNA, 5 ml buffer and
5 ml enzyme), post fragmentation clean-up with 1:2.86 volume
Agencourt Ampure RNAClean XP (Beckman Coulter, Pasadena,
CA, USA); post cDNA synthesis clean-up with 1:1.256 volume
Ampure XP Beads; post end repair, A-Tailing and adapter ligation
clean-ups with 1:1.86 volume Ampure XP Beads and post-PCR
library clean-ups with 1:16volume Ampure XP Beads. Addition-
ally, upon ligation of Illumina Adapters (Multiplexing Sample
Preparation Oligonucleotide Kit) each library was size selected
with two Ampure Bead steps (firstly, 1:0.76volume and secondly,
the supernatant from the first bind was taken for a 1:1.76volume
clean-up), selecting 200–600 bp fragments in 30 ml 10 mM Tris-
Cl, pH 8.5. Pre-PCR workflow was partially performed using a
Whole Genome Sequencing of RNA Viruses
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Beckman Biomek FX and post-PCR steps were performed using a
Beckman Biomek NXP and Biomek 3000.
The following custom primers (25 mM each) were used for the
PCR enrichment step:
Multiplex PCR primer 1.0
59-AATGATACGGCGACCACCGAGATCTA-
CACTCTTTCCCTACACGACGCTCTTCCGATCT-39
Index primer
59-CAAGCAGAAGACGGCATACGAGAT[INDEX]CAGT-
GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-39
Amplified libraries were analysed for size distribution using the
Agilent Tapestation 2200 D1K. Libraries were quantified by
quantitative RT-PCR using Agilent qPCR Library Quantification
Kit and a Mx3005P instrument (Agilent) and relative volumes
were pooled accordingly. Finally, a second quantitative RT-PCR
was performed to measure the relative concentration of the pool
compared to a previously sequenced mRNA library in order to
determine the volume to use for sequencing.
Improved Fragmentation Library Preparation for
Illumina. To increase the library insert size of the sequenced
libraries and to further investigate secondary structures within the
Norovirus genome, a modified fragmentation method was
developed. The total RNA was fragmented using 2 ml fragmen-
tation buffer diluted 1:4 in nuclease-free water (fragmentation
buffer included in the NEBNext mRNA Library Prep Master Mix
Set), incubated at 94uC for 5 minutes, placed immediately to ice
and followed by adding 2 ml stop solution (not diluted). Post-
fragmentation clean-up through to adapter ligation clean-up were
as above. Size selection was omitted to avoid losing longer
fragments, and instead, an additional bead clean-up after ligation
was performed to remove any remaining adapter dimer prior to
PCR amplification.
Illumina Amplicon Library Preparation. Amplicons were
quantified and quality assessed using Quant-IT Qubit dsDNA
High Sensitivity Assay (Invitrogen) and 1% E-gel (Invitrogen)
respectively. Fifty nanograms were sheared to 400 bp using
CovarisTM DNA Shearing (Woburn, MA, USA) and concentrated
using 1:16 volume Ampure XP Beads. Eluted DNA fragments
were then processed through standard library preparation
procedures (end repair through to Ampure Bead size selection
using the NEBNext DNA Library Prep Master Mix Set for
Illumina). Post-reaction clean-ups were 1:1.86 volume Ampure
XP Beads and post-PCR libraries were cleaned with 1:16volume
Ampure XP. Ten cycles of PCR amplification were performed
using custom primers as above, and the final library was pooled
with Norovirus positive samples from the pilot study.
Sequencing. Multiplex libraries were prepared using bar-
coded primers and a median insert size of 150 bp (increased to
200 bp with the modified method). The pooled libraries from 3
initial Norovirus and 2 HCV samples were sequenced on an
Illumina MiSeq with 150 bp paired end reads following standard
Illumina protocols. An average of 0.5 Gb of sequence was
produced per sample. A larger pool of 77 Norovirus samples
was sequenced on an Illumina HiSeq 2000 with 100 bp paired end
reads following standard Illumina protocols.
Data analysis. Reference sequences for each organism were
obtained from GenBank. For Norovirus the sequences were GII.4,
and the Norovirus Hu/GII.4/Orange/NSW001P/2008/AU was
used as a reference (accession number GQ845367). This was
selected as the most common match to the Sanger sequenced
288 bp RT-PCR amplicon used in the diagnostic RT-PCR stage.
For HCV the reference sequence used was the subtype 3a strain
(accession number AF046866).
Sequences were mapped to the organism-specific reference
using Stampy v1.0.14 [25] with no BWA pre-mapping. Bases and
single nucleotide variants (SNVs) were called using the SAMtools
‘‘mpileup’’ command with options ‘-E -M0 -Q30 -q30 -o40 -e20 -
h100 -m2 -D -S’ and BCFtools [26]. Sites were filtered to avoid
unreliable calls using the following criteria:
a) A minimum depth of 5 reads at each position
b) A minimum average base quality of 10
c) A minimum SNV quality of 25
d) At least 75% of reads at the position support the call and the
position was called as homozygous
Positions were called as heterozygous based on the SAMtools
genotype calls. An evolutionary tree was created using BEAST
(Bayesian evolutionary analysis sampling trees) depicting all the full
genomic sequences with relatedness. Analysis was performed using
BEAST v.1.7.5 combining two random number seed chains (10
million iterations each, saving 1 in 1,000 iterations, with a 1
million iteration burn-in) using: HKY substitution; estimated
frequency; strict clock; and constant population size coalescent tree
prior. This maximum clade credibility tree was computed using
TreeAnnotator v.1.7.5 and plotted with Figtree v.1.4.0. [27].
The sequences reported in this paper have been deposited in the
European Nucleotide Archive Sequence Read Archive under
study accession number ERP002219. The Sanger sequences used
for validation for Norovirus comparison have been submitted to
EMBL under accession numbers HF952119-HF952135. For
HCV, the Sanger sequences used for comparison were Genbank
accession numbers GQ356201 and KC836883.
Results
1.) Proof of principle experiment using the Illumina
MiSeq bench-top sequencer: Norovirus and HCV
We chose two RNA viruses for the initial proof of principle
study; three faecal samples RT-PCR positive for Norovirus, and
two blood samples RT-PCR positive for HCV. For the libraries
produced directly from total RNA, 0.12–1.90% (4,188/3,458,332
reads – 50,138/2,671,058 reads) of the total reads mapped to the
reference genomes (Table S2), indicating that a low percentage of
the total RNA was from the virus of interest. However, despite the
low percentage of reads which mapped, sufficient coverage of the
virus genome was obtained to achieve a near complete sequence.
The coverage of the sequence assembly varied, being lower at the
59 and 39 termini of genomes sequenced from cDNA, and at the
ends of each of the 7 overlapping PCR amplicons (Figures 1 and
2). This was expected due to the recognised difficulty of recovering
suitable short fragments for Illumina sequencing from the ends of
DNA molecules [28][29][30]. The regions of high and low
coverage in the RNA samples were consistent across different
genomes from the same organism (Figure 2), which suggest that
the amount of coverage obtained is due to an intrinsic property of
the viral RNA [31].
Single nucleotide variants (SNVs) were called using SAMtools
and BCFtools [26]. After filtering to remove unreliable base calls
(see Methods), 97.4–99.1% of the genome could be called in the
Norovirus samples, and 97.3–98.9% of the genome in the HCV
samples. The majority of the positions which could not be called
were clustered at the ends of the genome, and were removed
during filtering due to the limited depth of coverage (below 5
reads) and quality at each position.
Sanger sequencing for validation. The SNVs called from
our Illumina MiSeq sequencing approach were compared with
Whole Genome Sequencing of RNA Viruses
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those obtained from Sanger sequencing. For sample 1, 99.1% of
the genome could be called by both Sanger and Illumina
sequencing, and the base calls by both methods were identical.
As the Sanger sequencing for Norovirus was based on amplicon
PCR amplification, only partial sequence was obtained for sample
3 since one of the PCR fragments could not be amplified. For this
sample, 86.4% of the genome could be called using both methods,
and the base calls were all identical. Sample 2 failed repeatedly to
produce any PCR products and therefore no Sanger sequence was
available for comparison. We had specifically included it in our
pilot study to determine whether samples that could not be
sequenced by Sanger sequencing could be successfully sequenced
using the Illumina platform. Thus overall, for Norovirus we found
no differences in a total of 14,019 nt that could be directly
compared between Sanger and Illumina custom RNA-Seq
sequencing methods. One Norovirus sample (Sample 1) was
sequenced twice with Illumina technology, once using a library
obtained directly from total RNA (see above) and once from 7
PCR amplicons. Sequences obtained using both methods were
identical with the genome generated by Sanger sequencing.
Only one near full-length HCV Sanger sequence was available
(sample 4). Due to missing bases at the ends of the genome
produced by Sanger sequencing, only 8,051 bp (84% of the
genome) could be called by both sequencing methods. The
sequences differed at 2 positions. For sample 5, only a partial
Sanger sequence (1,491 nt) of the env gene was available. Of the
1,491 nucleotides which could be called by both methods (15% of
the genome), there were 5 SNV differences and a 1 bp insertion in
the Sanger sequence relative to the Illumina sequencing. Thus
overall, for HCV we found 8 variants in 9,542 nt that could be
directly compared between Sanger and Illumina RNA-Seq
sequencing methods, 1 variant per 1,193 nt.
Both viruses yielded heterozygous base calls by our SAMtools-
based variant calling pipeline, indicating the presence of within-
sample genetic variation. The three Norovirus samples showed 2,
3, and 2 distinct positions called as heterozygous, while the two
HCV samples had 117 and 131 positions called as heterozygous.
Although we did not investigate these positions further, they
indicate the potential to directly characterize within-host viral
diversity using Illumina sequencing.
2.) Validation using the HiSeq sequencer: Norovirus
To test our method on a larger scale, we sequenced 61
Norovirus patient samples on the HiSeq platform. All samples
were positive for Norovirus by RT-PCR prior to sequencing. To
determine the reproducibility of our approach, we split 15 larger
Figure 1. Coverage profiles of one Norovirus sample from amplicon and direct RNA sequencing. A – Coverage across the genome for
one Norovirus sample sequenced from PCR amplicons (others similar). Green and orange dotted lined mark the locations of the PCR primers used to
generate the amplicons. B – coverage across the genome for the same Norovirus sample sequenced directly from RNA.
doi:10.1371/journal.pone.0066129.g001
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volume samples into duplicates. Either two libraries were prepared
from the same extraction of total RNA (9 pairs), or RNA was
extracted from the same faecal sample twice and two separate
libraries were prepared (6 pairs). Additionally, one library
previously sequenced on the MiSeq platform was also sequenced
on the HiSeq (total 77 sequences generated). There was a four to
seven month time difference between the extraction and re-
extraction from the pairs of samples prepared from the same
original source material. Although incidental, this allowed us to
ascertain whether the integrity of the faecal material degraded
with time. In this total set of 61 patient samples, 16 had full
genomes produced by Sanger sequencing, enabling comparison
and validation.
Using the HiSeq platform, a mean of 4.6 million reads were
produced per sample. The proportion of reads that mapped to the
reference genome varied across the samples, ranging from 0.01%
to 97.98%; a wider range than seen in the three pilot MiSeq
samples (Table S2). Although greater variability would be
expected in a larger sample collection, this may also reflect
variability in the proportion of the original sample that comprised
the viral RNA of interest versus RNA from other sources. We
observed a significant correlation between the percentage of reads
which mapped to the reference genome and the viral titre
estimated by qPCR (rho = 0.4, p,0.0001, Figure S1).
Seventy-six out of 77 sequenced preparations produced
sufficient reads to allow 90–98.9% of the reference GII.4 genome
bases to be called (mean 97.0%). One sample yielded a low
number of reads so that only 4,449 (58.9%) of the reference bases
could be successfully called (sample 6). As with the pilot MiSeq
study, the bases which could not be called were clustered at the
ends of the genome with specific regions consistently yielding low
coverage (Figure S2). No differences in the called sequence of 15
duplicate pairs were observed. Of the 12 single samples and 4 pairs
of samples where Sanger sequencing was available, the base calls
were identical across all samples (total 118,757 nt, 148,421 nt
including the 4 repeated samples).
We used BEAST [27] to reconstruct the evolutionary tree
relating these 61 near-complete Norovirus genome sequences from
patient samples (Figure 3). Viruses clustered in space and time,
consistent with short-lived outbreaks, although divergent strains
could be seen occurring within the same time period during ward
outbreaks. Within spatio-temporal clusters, whole genome se-
quencing revealed low-level genetic variability (up to 13 SNVs).
Between clusters, genomes diverged by up to 268 SNVs.
Improved fragmentation analysis. Although the method
proved to be robust, it may suffer from the limitation that high
variation in coverage across the virus genome could require very
large numbers of sequence reads to achieve acceptable sequence
completeness (Figure S2). Since this could have arisen from
Figure 2. Coverage across the genome for two Hepatitis C samples sequenced directly from RNA.
doi:10.1371/journal.pone.0066129.g002
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Figure 3. Evolutionary tree created by BEAST (Bayesian evolutionary analysis sampling trees) depicting all the full genomic
sequences with relatedness (61 sequences, excluding repeated pairs). Clusters of genomes are visible among viruses sampled at similar
points in time. Whole genome sequencing gives adequate resolution to distinguish potential divergent viral strains within the same time, as
illustrated in clusters from January 2010, February 2011 and March 2011. WO=ward outbreak. Each node and branch has been coloured depicting
the posterior probability supporting that clade calculated by Bayesian analysis (Dark Blue = 1 (high); Light Red= 0 (low)). Analysis was performed
using BEAST v.1.7.5 combining two random number seed chains (10 million iterations each, saving 1 in 1000 iterations, with a 1 million iteration burn-
in) using: HKY substitution; estimated frequency; strict clock; and constant population size coalescent tree prior. This maximum clade credibility tree
was computed using TreeAnnotator v.1.7.5 and plotted with Figtree v.1.4.0.
doi:10.1371/journal.pone.0066129.g003
Figure 4. Comparison of the different fragmentation methods. A) fragment size distribution of a library prepared using the standard
fragmentation method (red) and a library prepared using the new fragmentation method (blue). B) the coverage across the genome for the standard
fragmentation sample (red) and the new fragmentation sample (blue). Data has been scaled as the difference from the median coverage for both samples.
doi:10.1371/journal.pone.0066129.g004
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interference of RNA secondary structures with efficient fragmen-
tation, a modified fragmentation method was adopted that
produced libraries with a wider distribution of insert sizes. This
modification smoothed out coverage appreciably, improving data
in those regions that previously were poorly represented (Figure 4).
This improvement offers the prospect of increasing the throughput
of samples from a single sequencing run.
Discussion
Here we describe a reproducible next-generation short-read
sequencing method based on a modified streamlined RNA-Seq
approach for producing near-complete genome sequences of
Norovirus and Hepatitis C virus. This method is scalable to batch
processing of large numbers of samples with a relatively modest
turn-around time of 4 weeks. The method is equally suited to rapid
bench-top sequencing with a turn-around of under a week (Figure
S3). The current cost of £60 per sample (consumables and
sequencing) is similar to that achieved for sequencing a bacterial
genome in our facility (Table 1). We have shown that in two
distinct clinical sample types there is sufficient virus RNA present
(as low as 0.01% or ,4,200 reads mapping to that respective
reference) to successfully undertake virus whole-genome sequenc-
ing. This is despite the presence of sequences from other sources
such as human RNA and, in the case of faeces, food and microbial
RNA. This improved method offers the prospect of large-scale
affordable studies of RNA viruses and could be adapted to routine
diagnostic laboratory workflows. An additional advantage of this
method is that no step requiring sequence-specific primers for
PCR amplification or bait-based enrichment is needed. This
feature limits the possibility of primer-based bias in the processing
of samples and provides the opportunity of bioinformatically
detecting any other known RNA virus at the same time.
Figure 5 shows a schematic representation of the various
methods available for sequencing RNA viruses. We have shown
that, for Norovirus, even for samples with a low titer (,300 copies
per microliter) it is possible to reconstruct near full genome
sequence data (Table S2). However, in cases where the total
available RNA is very limited and the viral load known to be ultra-
low, other strategies may be implemented. As recently described
the NuGEN Ovation RNA-Seq system provides a valid solution to
amplify RNA viral genomes while removing rRNA [32]. It should
be noted that this strategy adds to the cost of the preparation
(Table 1). Moreover, the Single Primer Isothermal Amplification
(SPIA) protocol relies on polyA degraded RNA species and non
polyA containing species are expected to be lost or to only provide
partial sequencing data.
One advantage of systems that can produce long cDNAs is the
possibility of using the Illumina’s Nextera kit which may greatly
reduce the time for library construction. However, this is a
speculative thought which has not been experimentally investigat-
ed. As such we prefer not to make hypothetical suggestions in the
setting of this report.
Our RNA-Seq based method requires only 12 cycles of PCR
amplification in total, while all amplicon or hybridisation based
methods will include over 30 cycles of PCR (Table 1), increasing
the likelihood of biases being introduced through amplification.
We encountered a high failure rate with amplicon based methods,
while our RNA-Seq based method was less susceptible to failures
in reverse transcription, implying that the method may be more
robust. The speed and throughput of the Illumina workflow make
it a desirable approach for large numbers of samples (Figure S3),
being able to prepare up to 96 samples in 3–3.5 days and
sequencing them either in batches of 6 samples over 27 hours
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using the MiSeq or as a single batch of 96 over 14 days on a
HiSeq.
The reproducibility of our sequencing method was demonstrat-
ed using multiple replicates of the same clinical samples (15 pairs)
by the Illumina sequencing platform characterized by traditional
Sanger sequencing. In the case of Norovirus, the sequences from
strains associated with multiple temporally linked cases suggests
that whole genomic sequence analysis is likely to provide a robust
approach to tracking outbreaks. Furthermore, such high resolution
data will also give rapid turnaround data on viral genotypes (e.g.
HCV or HIV) and recognition of sudden shifts in the predominant
capsid variant of Norovirus in general circulation [33][34].
The depth of genome coverage enabled identification of within-
sample sequence variation that probably reflects the presence of
multiple, closely-related viral variants within the patient, some-
times known as ‘‘quasi-species’’ [35]. Analysis of our data revealed
a small number of positions variable within individual Norovirus
patients (up to 3 sites in one sample), which is the first evidence of
low-level within-patient diversity in this virus. In contrast HCV
exhibited a larger number of sites variable within individual
patients (up to 131), consistent with previous reports [36].
Although mapping or assembly of short-read sequences obtained
by next-generation sequencing has limited scope for reconstructing
full-length virus haplotypes, useful insights may nevertheless be
gained from the marginal frequency distribution of variants.
The success of our sequencing approach depends on bioinfor-
matics methodology for recognising the viral sequences of interest
as a minor component of a heterogeneous population of
sequences. The mapping-based approach used here can be
regarded as a prototype for characterizing viral genomes, and
other strategies using assemblers of viral sequences may be more
powerful. These include using a de novo population consensus
assembly [37][38] which may prove useful particularly when the
virus population contains variation in genetic organisation such as
large insertions and deletions. Current de novo assemblers have
difficulty in robustly assembling virus genomes accurately in the
presence of within-sample variability, contaminants, and variable
sequence coverage [39]. However, new tools are becoming
available which may combat these issues [40].
The improvements we describe in generating near whole viral
genome sequences over sequences produced by Sanger sequencing
[33] or Roche 454 sequencing [41] are likely to be superseded by
future improvements in sequencing platforms, such as longer read
and simplified sample preparation which requires lower input
material [42]. It is expected that complete genome sequences may
ultimately be obtained directly from clinical samples using these
enhanced sequencing platforms and improved bioinformatics
analysis in clinically relevant time-frames (e.g. within hours of
receipt in a laboratory). These future methodologies may facilitate
the discovery of new viruses once processing of all clinical samples
in this way becomes routine practice. Such changes would
revolutionise the diagnosis of viral infections and would also
promote new avenues of research into virus evolution, antiviral
resistance and personalized medicine approaches to treating
specific viral genotypes.
Supporting Information
Table S1 Details of primers used for producing the
seven overlapping amplicon fragments. Internal primers
have been included with the abbreviation INT followed by
number. All primers listed were designed in-house. F= forward;
R= reverse.
(DOCX)
Table S2 Data generated by both Illumina platforms.
Samples with * in brackets denote samples that were originally
sequenced using the MiSeq. Samples with alphabetical suffices (a
and b) were pairs of samples re-sequenced from the same
extraction of total RNA on the Illumina HiSeq to confirm
reproducibility. Samples with Roman suffices (i and ii) denote pairs
of samples where RNA extracted from the same faecal sample
twice and two separate libraries prepared.
(XLS)
Figure 5. Schematic representation of different strategies for viral genome resequencing. A) Total RNA library: all the RNA species
present in the sample are sequenced, no assumption on which genome is present, B) Hybridisation capture of a mRNA library: a good reference
genome is needed to design the probes for capture, C) PCR enrichment: the desired genome is amplified from cDNA, a reference genome is needed
to design specific oligos. Red lines, genomes of interest; Blue segments, Illumina adapters; Black lines, other RNA species.
doi:10.1371/journal.pone.0066129.g005
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Figure S1 A comparison of the viral titre of each sample assessed
by qPCR, and the percentage of reads obtained from each sample
which mapped to the Norovirus reference genome, showing the
correlation between the two measures (rho = 0.4, p,0.0001).
(TIFF)
Figure S2 Coverage and percentage plots of 76 Nor-
ovirus HiSeq sequences. A – percentage of the 76 Norovirus
HiSeq samples which could be called at each position in the
genome, averaged across 5 bp windows. B – the median, tenth
percentile, and ninetieth percentile of the coverage across the
genome for the 76 HiSeq samples. Note: 10th percentile is 0 where
not shown.
(EPS)
Figure S3 Timelines associated with platforms per
optimum batch size per lane. Batch sizes are calculated by
a combination of required coverage and the maximum multiplex-
ing capacity available at the time. Sanger sequencing timeline does
not take into account the high failure rate (71% in our study).
PE = paired ends
(EPS)
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